Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNSTAR
2024-515600-39-00Phase 4Completed
- Sponsor
- Groupement des Hôpitaux de l'Institut Catholique de Lille
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in rheumatoid arthritis (RA) comparing Subcutaneous abatacept with Subcutaneous tocilizumab (2 arms). Primary endpoint: Change in Clinical Disease Activity Index (CDAI) at 6 months. Started Jul 2024; status: completed.
02
Drugs
abatacepttocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2024-515600-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515600-39-00.